Kardigan Files for U.S. IPO to Fund Three Late-Stage Cardiovascular Drugs
Kardigan submitted paperwork for a U.S. initial public offering. The filing states the proceeds will support three late-stage drug candidates aimed at the underlying mechanisms of cardiovascular disease.
BloombergU.S. initial public offering. The company stated that funds raised will support development of three late-stage drug candidates designed to address root causes of cardiovascular diseases.
U.S. securities regulators.
Kardigan indicated the offering will provide capital for ongoing clinical programs without specifying share count or pricing range.
The three candidates target biological pathways linked to cardiovascular conditions. Kardigan described the programs as late-stage, indicating they have advanced through earlier safety and dosing studies. No timeline for completion of trials or regulatory submissions was included in the filing.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
Substrate placeholder — needs reviewIran Suspends Indirect Talks With U.S. Amid Escalating Israel-Hezbollah Conflict in Lebanon
Iran has stopped all message exchange with the United States, including ongoing talks, in response to Israel's expanded offensive in Lebanon. The suspension was reported by Tasnim News Agency, which is affiliated with the Islamic Revolutionary Guard Corps according to the Jerusal…
france24.comIranian Official: Tehran Manages Strait of Hormuz and Will Not Allow Maritime Blockade
Mohsen Rezaei stated that Iran controls the Strait of Hormuz and will not allow a maritime blockade to continue. Oil prices rose 8 percent on the day of the statements.
Al JazeeraGreece Reviews Asylum Status for Syrians and Afghans After Conflicts End
Greek authorities began reviewing protection status for Syrians and Afghans in February after the end of Syria's civil war and the 2021 Taliban takeover. The reviews target men and coincide with new returns legislation.